Literature DB >> 15043750

Neo-adjuvant STI571 therapy for high-risk gastrointestinal stromal tumour.

Chien-Liang Liu, Ming-Jer Huang, Shee-Chan Lin, Kuo-Ming Chang, Chin-Yuan Tzen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15043750     DOI： 10.1111/j.1445-2197.2004.02973.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN： 1445-1433            Impact factor:   1.872


× No keyword cloud information.
  2 in total

1.  Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor.

Authors:  Ying-Yong Hou; Yang Zhou; Shao-Hua Lu; Wei-Dong Qi; Cheng Xu; Jun Hou; Yun-Shan Tan
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

2.  Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

Authors:  Burton L Eisenberg; Jonathan Harris; Charles D Blanke; George D Demetri; Michael C Heinrich; James C Watson; John P Hoffman; Scott Okuno; John M Kane; Margaret von Mehren
Journal:  J Surg Oncol       Date:  2009-01-01       Impact factor: 3.454
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.